Osteoblasts respond in direct and indirect ways to estrogens, and age-dependent changes in hormone levels and bone health can be limited by focused hormone replacement therapy. In this study, we report the release and isolation of an estrogen receptor agonist from osteoblast cultures. This entity reprises many aspects of estradiol activity in isolated osteoblasts, but differs from authentic estradiol by several biochemical and physical criteria. At levels that occur in conditioned medium from differentiating osteoblast cultures, the agonist directly drives gene expression through estrogen-sensitive response elements, activates the obligate osteoblast transcription factor Runx2, and potently enhances Smad-dependent gene expression in response to TGF-␤, but exhibits relatively lesser suppressive effects on gene expression through C/EBP and AP-1-binding protein transcription factors. Estrogen receptor agonist activity is resistant to heating at 100°C and separable from the bulk of the remaining alcohol-and hexane-soluble molecules by C18 chromatography. MS and molecular fragmentation analyses predict a Mr of 415.2 to 437.2. Therefore, in addition to earlier studies showing that osteoblasts readily respond to and metabolize various sex steroid-like substrates, we find that they also generate a potent estrogen receptor agonist during differentiation in vitro. Changes in the availability of a molecule like this within bone may relate to differences in skeletal integrity with aging or metabolic disease.
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intracrine ͉ selective estrogen receptor modulator ͉ steroid S ex steroids cause direct genomic transcriptional effects through specific receptors that contain ligand binding, dimerization, DNA binding, and gene transactivation domains. They also cause indirect stimulatory or inhibitory effects through complexes composed of activated hormone receptor and other transcription factors or through variations in the activation potential of other transcriptional components (1) (2) (3) (4) (5) (6) The skeleton is a well recognized target for sex steroids. Bone fragility is notable when sex steroid levels fall in women after menopause, in elderly males, or after sex organ ablation (7) (8) (9) (10) (11) . In such cases, bone loss follows a release from native constraints on bone resorption that largely result from changes in growth regulators expressed by osteoblasts and from opposing effects on osteoblast and osteoclast activation and apoptosis, leading to an overall increase in bone remodeling (12) (13) (14) (15) (16) . Importantly, imbalances in bone remodeling are restored by sex hormone replacement therapy. Regardless of a clear benefit for bone, use of native sex steroids risks inappropriate gene activation in other tissues. The possibility of breast, cardiovascular, and prostate disease that can occur in this context (17) (18) (19) has driven the search for sex hormone receptor modulators with tissue-or function-restricted effects. However, the value of agents like these may be complicated by steroid and precursor metabolizing enzymes expressed by osteoblasts (3, 20, 21) .
Many cells used to evaluate sex steroid receptor modulators express little or no endogenous sex steroid receptors. This offers a select advantage to introduce native or mutated receptors transgenically and thereby discriminate effects through individual estrogen or androgen receptors, through direct events that require sex steroid receptor binding to DNA, or through indirect interactions with other transcription factors. In this regard, osteoblasts from fetal rat bone express little functional sex steroid receptor but acquire the ability to drive complex direct and indirect responses after transgenic receptor expression (3, 12, 20, 22, 23) . Still, some studies suggest that endogenous estrogen receptor ␣ (ER␣) levels increase during late-stage osteoblast differentiation (24, 25) . To address this further, we investigated whether osteoblasts acquire a functional sex steroid response during differentiation in vitro. In this study we report an increase in ER␣ dependent activity, through expression of an endogenous agonist, which occurs during this process.
Results
Endogenous ER␣-Dependent Gene Expression in Differentiating Osteoblast Cultures. In an effort to determine whether osteoblasts express functional ER␣ during early stages of in vitro differentiation, we found no significant endogenous gene expression through canonical estrogen response elements (ERE) without transgenic ER␣ expression in young (7-day-old) or differentiating (21-day-old) cultures. Surprisingly, reporter gene activity through ER␣ increased significantly without added ligand in the 21-day-old cultures. No appreciable endogenous ER␣-dependent activity occurred in 7-day-old cultures or in 21-dayold cultures that express androgen receptor (AR) and reporter driven by androgen response elements (ARE) (Fig. 1A Upper) . At all times, however, the cells were fully competent to respond to added estradiol (17␤E) or dihydrotestosterone (DHT) (Fig.  1 A Lower, and other studies below). These findings suggested that later stage osteoblast cultures acquired the ability to elaborate an endogenous ER␣ agonist-like activity. This activity was fully dependent on ER␣ expression (Fig. 1B) and was maximal between 21 and 35 days of culturing (Fig. 1C Left) when no significant AR-dependent activity was observed (Fig. 1C Right) . Like the effect of 17␤E, ER␣ agonist-like activity was potently suppressed by the ER antagonist ICI 182780 (ICI) (Fig. 1D) . ER␣ activation may also occur indirectly by kinase cascades induced by intrinsic osteoblast growth factors like insulin-like growth factor (IGF)-I (26, 27) . However, endogenous ER␣ activation was not suppressed by staurosporine, PD-98059, or SB-203580, which inhibit multiple kinases including protein kinase C, p38 MAP kinase, or MEK [supporting information (SI) Fig. S1 ].
Release of a Soluble ER␣ Agonist. Based on these observations, we surmised that osteoblasts in later stage culture could express and possibly release an endogenous ER agonist. Correspondingly, 21-day-old cultures were washed exhaustively to deplete medium and serum components and refed serum-free, phenol red-free medium for 24 h. Conditioned medium (CM) recovered from refed cultures was then tested on 7-day-old cells, where it potently drove ER␣-dependent gene expression ( Fig. 2A) . Elaboration of ER␣ agonist activity in 24 h CM increased throughout at least 28 days of culture, and its effectiveness was also blocked by ICI 182780 (Fig. 2B) . Using 21-day-old cultures as a model of ER␣ agonist expression, we found virtually no activity in CM collected during the first hour after refeeding, whereas it was released continuously during 6 to 96 h of incubation in serumfree medium. In contrast, although alcohol soluble extract from the cell layer of 21-day-old cultures contained significant agonist activity immediately after exhaustive washing, this remained relatively constant throughout 96 h (Fig. 2C) . Therefore, later stage cells accrued a pool of ER␣ agonist that appeared to be released and replenished during this period. Although CM caused potent ER␣ agonist activity, it failed to induce androgen, progesterone, or glucocorticoid sensitive gene promoter activity in cells that were clearly responsive to added steroid (Fig. 2D ). Other studies suggest that ER agonist-like activity might result from cell culture components such as bisphenol plastic derivatives (28) or perhaps phenol red added to many culture media (29) . However, cells grown on glass rather than plastic also released potent ER␣ agonist activity (Fig. 2E) , and in agreement with other studies (30) , addition of phenol red had no effect without or with 17␤E in 7-day-old cultures, or on endogenous ER␣ agonist activity or 17␤E in 21-day-old cultures ( Fig. 2F ). CM also enhanced gene expression in 7-day-old cultures through ER␤ (31) , which may function independently of ER␣ in bone remodeling in females (32) . Whereas basal activity was Ϸ10-fold higher with ER␤ relative to ER␣, the relative stimulatory effect of CM or 17␤E was significantly less, and no activity through ER␤ was evident in 21-day-old cultures ( Fig. S2) . Also, CM activated ER␣ in human SaOs-2 osteoblast-like cells, and CMs from confluent 7-day-old SaOs-2 and MG63 human osteoblast like cultures were also active (Fig. S3 ), albeit to a lesser extent. The human osteoblasts did not survive long-term culture, however, presumably due to their derivation from osteosarcomas and unrestricted growth potential, preventing analysis of potentially higher ER␣ activator levels at later times in serum-free medium.
Differential Effects on Osteoblast Activity. With ER␣, CM drove ERE-dependent gene expression with a potency equivalent to Ϸ1 nM 17␤E (Fig. 3A) . Like 17␤E, it increased the activation potential of the obligate osteoblast transcription factor Runx2 in control and prostaglandin E2 (PGE2)-treated osteoblasts (Fig.  3B Upper) . It also decreased the stimulatory effect of PGE2 on IGF1 gene promoter activity (Fig. 3B Lower) , although with somewhat reduced potency. Furthermore, CM enhanced the stimulatory effect of TGF-␤ on Smad-dependent gene expression (Fig. 3C Upper) to a relatively greater extent than 1 nM 17␤E. By contrast to 17␤E however, the ER␣ agonist, at levels which occur in CM, failed to suppress AP-1-dependent gene expression in TGF-␤ activated cells (Fig. 3C Lower) .
Characterization Studies. By various criteria described above, the ER␣ agonist in CM shares several, but not all, qualitative or quantitative characteristics with 17␤E, predicting expression of a selective estrogen receptor modulator. Initial studies showed that the activity in CM was resistant to 30-min incubation at 100°C
, soluble in 80% ethanol (Fig. 4A) , removed by charcoal stripping (Fig. 4B) , and extracted with methanol and hexane (Fig. 4C) , consistent with a lipophilic compound. Material that survived 100°C and alcohol extraction was applied to an openend Sep-Pak C18 resin cartridge and step-gradient eluted with methanol, by which ER␣ agonist activity was released at 75-80% methanol (Fig. 4D) . By electrospray MS, the two fractions with the majority of ER␣ agonist activity each contained multiple, partly overlapping, species of various relative M r . The two active samples were dried and refractionated by C18 HPLC with a linear acetonitrile gradient in 0.1% trifluoroacetic, by which ER␣ agonist activity resolved into a primary peak at Ϸ50% acetonitrile, well removed from the bulk of UV light (254 nm)-absorbing materials. The amount of ER␣ agonist recovered in these highly purified fractions was equivalent to 0.3 nM 17␤E or about 50-70% of maximal activity when assayed through ERE. A second minor activity peak eluted at Ϸ53% acetonitrile by this assay (Fig. 4E, Top and Middle) . Whereas few if any genes expressed by osteoblasts are known to be driven directly through ERE, the oxytocin gene promoter contains a well recognized ERE (33) . When the HPLC fractions were assayed for activity through the native oxytocin gene promoter, the earlier eluting fraction induced a 40-to 60-fold increase in reporter gene expression (Fig. 4E Bottom) . However, this was only Ϸ2-10% of the increase that occurred in response to 0.3 nM 17␤E (data not shown). By contrast, the secondary peak was inert on oxytocin gene promoter activity and is not addressed further. By both Fourier transform and micromass Q-TOF MS, samples from the primary activity peak revealed three minor species at M r 353.27 (14% of total), 381.30 (14% of total), and 415.21 Da (12% of total), and a major species at M r 437.19 (60% of total), with an error range of 5 ppm. Of these, the only species common to the many molecules in the two fractions from open end C18 chromatography is the M r 437.19 species. Typically, the difference between the M r 415.21 and 437.19 species is considered to be due to a sodium atom, and together these species make up Ͼ70% of the active material from C18 HPLC. MS 2 fragmentation yielded a new, predominant species at M r 119.08. The 119.08 species may represent a side chain or an internal fragmentation product, but at present no further structural information of these compounds is definitive. By these several criteria, therefore, the most purified sample of ER␣ agonist in CM from differentiating osteoblasts contained a low M r lipophilic molecule that was functionally and physically dissimilar to 17␤E (M r 272.39).
Discussion
In this study, we report that differentiating osteoblasts express an endogenous ER␣ agonist that reproduces some, but not all, of the biochemical effects induced by 17␤E in these cells. Earlier evidence showed that osteoblasts may control some aspects of ER␣ activation locally within bone. Some studies revealed greater ER␣ expression in parallel with osteoblast differentiation (24, 25) , although no evidence correlated this with an increase in ER␣-dependent function. Other studies showed that osteoblasts can metabolize various substrates into potent ER␣ agonists through endogenous aromatase (21) or 3-ketoreductase (20) activities or inactivate some ER␣ agonists through endogenous 3-hydroxysteroid dehydrogenase expression (3) . Local production of estradiol-like molecules therefore completes the loop of an endogenous ligand, receptor, and response system within a single cell type. An important role for 17␤E in various aspects of skeletal growth and integrity is well known, and replacement therapy with native or synthetic ER modulators has historically been a potent adjunct to maintain bone mass and prevent fractures in postmenopausal women. Increased incidence of metabolic disease with certain ER modulators in nonskeletal tissues instills valid concerns, however, and may limit the use of some of these agents (34, 35) . ER modulators have complex direct and indirect effects on gene expression that can differ in part from 17␤E and often appear tissue restricted (6, 36) . In addition, even within osteoblasts, 17␤E itself can have complex stimulatory and inhibitory effects. Although it directly enhances gene expression through ER␣ binding to ERE, it can also indirectly enhance the transcriptional potential of nuclear factor Runx2, enhance or suppress independent aspects of TGF-␤ activity, and suppress gene expression through members of the C/EBP transcription factor family (12-14, 22, 23) . In the case of Runx2 and TGF-␤, this may help to enhance bone mass through effects on select phases of differentiated osteoblast function. In the case of C/EBP␦, this may account in large part for reciprocal, inverse changes in local and systemic expression of IGF-I that occur before and after menopause, and after hormone replacement therapy (37, 38) . The ER␣ agonist in osteoblast CM tends to reprise more fully the stimulatory effects of 17␤E on ERE, Runx2, and TGF-␤ activity, whereas it appears to be a less potent suppressor of C/EBP and AP-1 binding protein-dependent gene expression. Some effects of ER agonists might involve other membrane components such as G protein-coupled receptor GPR30 (39) . However, GPR30 activation can increase cAMP, which directly activates the IGF1 gene promoter (12, 27, 40) ; occur in response to ICI 182780; and involve MAP kinase (39), none of which are consistent with our results. ER␣ activators can also increase Runx2 mRNA expression in subconfluent mouse osteoblasts (41), but we found no increase in nuclear Runx2 in 17␤E-treated rat osteoblasts (22) . Still, future studies may reveal other effects in response to CM.
These and characteristics derived from MS indicate that the CM-derived ER␣ agonist is functionally and physically dissimilar to 17␤E. Furthermore, assuming that virtually all of the 17␤E in culture medium before serum starvation accumulates as a cell-associated component and is released during CM preparation, this can account for no more than 2-5% of the activity in CM. Unlike effects that occurred with ER␣, no endogenous AR activator was evident in differentiating osteoblasts during 5 weeks of culture, and treatment with aromatase inhibitors had no immediate or cumulative effect on endogenous ER␣ agonist activity or its release into CM in 3-week-old cultures (Fig. S4) . These findings together suggest that the CM-derived agonist might not originate from endogenous androgen-like precursors like testosterone, androstenedione, or their metabolites that can activate ARE-driven gene expression through ARE (T.L.M. and M.C., unpublished results). However, even more prolonged exposure to aromatase inhibitors may be necessary to block conversion of these or other facile substrates that escape ready detection due to rapid metabolism. Still, transgenic overexpression of 17␤-hydroxysteroid dehydrogenase reduced the stimulatory effect of either the CM-derived agonist or 17␤E by 80%-90% (Fig. S5) , predicting a degree of structural similarity between them. The possibility that local release of an ER␣ agonist has a protective role in bone during some phases of bone growth and remodeling, or that it may become a useful tool to maintain bone in some metabolic states, is an intriguing extension of our current observations.
Materials and Methods
Cells. Primary osteoblast-enriched cultures were isolated from parietal bones of 22-day-old Sprague-Dawley rat fetuses (Charles River Breeding Laboratories) as approved by the Yale Institutional Animal Care and Use Committee. Sutures were dissected and cells were released by five sequential collagenase digestions. Cells pooled from the last three digestions, which express features of differentiating osteoblasts, were plated at 4,000/cm 2 in Dulbecco's modified Eagle's medium supplemented with 10% FBS and 100 g/ml ascorbic acid (42, 43) and grown for various time intervals before transfection or treatment.
Plasmids. ER␣-, AR-, progesterone receptor-, and glucocorticoid receptordependent gene expression were assessed with luciferase reporter plasmids containing specific hormone response elements, without or with coexpression of homologous steroid receptors, as previously described (3, 20, 22) . Runx activity was assessed with luciferase reporter plasmid 5XGAL4 driven by five GAL4 response elements in cells cotransfected with an expression plasmid encoding a Runx2-GAL4 DNA binding domain fusion protein (3, 22) . Smaddependent gene expression was assessed with luciferase reporter plasmid SBE4 driven by four Smad response elements (22) , and IGF1 gene promoter was assessed with luciferase reporter plasmid 1711b-Luc, which contains a highly sensitive C/EBP response element in exon 1 that is rapidly activated in a protein kinase A-dependent way by PGE2 (40) , and is significantly repressed by activated ER␣ (12, 23) .
Transfections. Promoter-reporter fusion plasmids, gene expression plasmids, or empty parental vectors were pretitrated for expression efficiency and transfected with reagent LT1 (Mirus). Cultures were exposed to an optimal amount of reporter plasmid (37.5 to 75 ng/cm 2 ) or expression plasmid (10 to 75 ng/cm 2 ) in phenol red-free medium supplemented with 4% charcoal stripped serum. Transfected cells were cultured for another 24 -48 h and then treated in phenol red-free, serum-free medium as indicated in the figures. The cells were rinsed and lysed, and supernatants were analyzed for reporter gene activity and corrected for protein content. To account for competition among plasmids for limiting transcriptional components, control cultures were transfected with a compensating amount of empty vector. Transfection efficiency was assessed in parallel in cells transfected with positive and negative reporter plasmids (3, 20, 22) .
CM Preparation. Cells were cultured for varying intervals in 10-cm-diameter Petri dish cultures in 10 ml of growth medium supplemented with 10% FBS. After various intervals, medium was aspirated, and cell layers were washed six times with phosphate-buffered isotonic saline and refed for 0 -96 h with 5 ml of phenol red-free, serum-free medium. CM was collected at various time points before assay or for further processing. Cell layers were rinsed six times and extracted with 1 ml of 95% ethanol.
Chromatography. CM was lyophilized to dryness, redissolved in water, heated to 100°C for 30 min in a boiling water bath, centrifuged at 1,000 ϫ g to remove insoluble material, and relyophilized. Residue was redissolved in 80% ethanol and stored at Ϫ80°C overnight, and alcohol soluble material was collected by centrifugation and redried in a vacuum centrifuge. The material was redissolved in 80% ethanol, and an aliquot was diluted in water to Ͻ5% ethanol and applied to a prewashed open-end Sep-Pak Vac 20cc cartridge packed with 5 g of C18 resin. Flow through was collected, and bound material was water washed and eluted with a step gradient of 50 -100% methanol in 10% increments. Dried samples were redissolved and tested for ER␣ agonist activity. Active samples were dried and refractionated by C18 HPLC with a 60-ml, 30 -70% linear gradient of acetonitrile in 0.1% trifluoroacetic acid at 1.5 ml/min. Samples were dried, redissolved, and tested for activity.
MS Analysis.
Samples were supplied to the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University, which analyzed them for Mr by Fourier transform and micromass Q-TOF spectrometry (3).
Statistical Analysis. Differences were assessed by one-way ANOVA with Tukey post hoc analysis in SigmaStat (Jandel Scientific) from six or more replicates and two or more independent cell preparations. Significant difference was assumed by a P value Ͻ0.05.
